Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	25.78B +195.9%
Revenue (ttm)	5.36B -40.8%
Net Income	303.18M -75.8%
EPS	0.61 -75.7%
Shares Out	575.99M
PE Ratio	73.13
Forward PE	n/a
Dividend	5.69 (12.90%)
Ex-Dividend Date	Jul 31, 2025

Volume	57,069
Average Volume	258,197
Open	44.02
Previous Close	44.76
Day's Range	43.76 - 44.76
52-Week Range	39.80 - 67.30
Beta	-0.07
RSI	52.94
Earnings Date	Mar 31, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 4,861
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

In 2024, Sunshine Lake Pharma's revenue was 3.72 billion, a decrease of -40.84% compared to the previous year's 6.29 billion. Earnings were 482.71 million, a decrease of -75.78%.

Financial numbers in CNY